These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28078563)

  • 1. Changes in first-line injectable disease-modifying therapy for multiple sclerosis: predictors of non-adherence, switching, discontinuation, and interruption of drugs.
    Degli Esposti L; Piccinni C; Sangiorgi D; Perrone V; Aledda L; Marrosu MG; Lombardo F
    Neurol Sci; 2017 Apr; 38(4):589-594. PubMed ID: 28078563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
    BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
    Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
    Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.
    Arroyo E; Grau C; Ramo-Tello C; Parra J; Sánchez-Soliño O;
    Eur Neurol; 2011; 65(2):59-67. PubMed ID: 21212677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J; Gomes T; Mamdani M; Manno M; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):429-33. PubMed ID: 21515501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis.
    Halpern R; Agarwal S; Dembek C; Borton L; Lopez-Bresnahan M
    Patient Prefer Adherence; 2011 Jan; 5():73-84. PubMed ID: 21423591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.
    Correia I; Marques IB; Sousa M; Batista S; Ferreira R; Nunes C; Macário C; Cunha L; Sousa L
    J Clin Neurosci; 2016 Nov; 33():73-78. PubMed ID: 27542939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence and persistence to drug therapies for multiple sclerosis: A population-based study.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Melesse DY; Kingwell E; Zhao Y; Tremlett H
    Mult Scler Relat Disord; 2016 Jul; 8():78-85. PubMed ID: 27456879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
    Limmroth V; Gerbershagen K
    Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report.
    Berkovich R
    Mult Scler Relat Disord; 2017 Oct; 17():123-127. PubMed ID: 29055441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 19. Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study.
    Sabidó-Espin M; Munschauer R
    BMC Neurol; 2017 Mar; 17(1):57. PubMed ID: 28335743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.